HMM: Nanobody-drug conjugates hijack the human vitamin B12 uptake route. “A major challenge in cancer therapy is selectively targeting cancer cells over healthy ones. A recent study by the Locher group (IMBB) describes the development of camelid single-domain antibodies (nanobodies) that selectively deliver cargo to cells by hijacking the cellular vitamin B12 uptake pathway, which is in high demand in cancer cells.”